Skip to Content


Treatment for Neuropathic Pain, Postherpetic Neuralgia, Fibromyalgia, Diabetic Neuropathy, Epilepsy

Pfizer Statement on Regulatory Status of Lyrica

NEW YORK, September 02, 2004 -- In response to media inquiries, Pfizer said it has received approvable letters from the US Food & Drug Administration for three indications for Lyrica (pregabalin): neuropathic pain associated with diabetic peripheral neuropathy, postherpetic neuralgia, and as adjunctive therapy in the treatment of partial seizures in adults. Pfizer received a non-approvable letter for Lyrica for the treatment of generalized anxiety disorder.

Pfizer said it is continuing to work closely with the FDA during the ongoing regulatory review to resolve open issues on all indications and labeling.

In the European Union, Lyrica received marketing approval in July 2004 for the management of peripheral neuropathic pain and as an adjunctive therapy in the treatment of partial seizures.

For further information, please visit

Posted: September 2004

Related Articles

Lyrica (pregabalin) FDA Approval History

More News Resources

Subscribe to our Newsletter

Whatever your topic of interest, subscribe to our newsletters to get the best of in your inbox.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.